BK1251 Digital Health
- 387.952
- -8.275-2.09%
Zhongan Online (06060.HK): The underwriting profit trend is becoming more and more clear, and the technology business has room for imagination
Big Bank Rating | Dahua Jixian: Lowering Ali Health's Target Price to HK$4 to Maintain “Buy” Rating
JD Health (06618.HK): Three-party merchant ecosystem construction accelerates full coverage of online and offline medical scenarios
Zhongan Online (6060.HK): Maintaining high premiums, changing profits from loss to profit
Dingdang Health (09886.HK): 2023 performance falls short of market expectations, steady growth in core business
Ali Health (0241.HK) 2HFY24 Performance Forecast: High base effect puts pressure on revenue growth in the short term
JD Health (6618.HK): Gross margin is expected to continue to recover, and service revenue is expected to maintain rapid growth
Zhongan Online (06060.HK) Company Review Report: The rapid growth of the four major ecological premiums, Zhongan International no longer combined to bring one-time profit and loss
Zhongan Online (6060.HK): Insurance business reverses losses and reveals major assets
Zhongan Online (6060.HK): Investment improvements drive profits and reverse losses in various sections
Ping An Good Doctor (01833.HK): Continue to deepen collaboration with the Group to deepen the healthcare and pension ecosystem
JD Health (06618.HK) 2023 Annual Report Performance Review: Reducing Costs and Increasing Efficiency to Develop New Quality Productivity Layout Medical Services
JD Health (6618.HK): Expanding the Tripartite Merchant Ecosystem to Help Return to an Endogenous Growth Path
Good Doctor Ping An (1833.HK): Focus on new developments after strategic transformation
JD Health (6618.HK) 2023 Report Review: The number of merchants on the three sides increased dramatically, and the big model helped reduce costs and increase efficiency
JD Health (6618.HK): Performance growth exceeds expectations, omnichannel business layout accelerates
Nomura Adjusts JD Health's Price Target to HK$44 to HK$37, Keeps at Buy
Dahua Jixian: Strategic business is expected to achieve double-digit growth and maintain Ping An Good Doctor (01833) “buy” rating
Ping An Good Doctor (01833)'s front-end and back-end strategy progressed smoothly, and Daimo raised the target price to HK$21
UBS: Strategy 2.0 has achieved results and a target price of HK$20 for Safe Doctor (01833)